Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on PURECIRCLE LTD. We currently have 18 research reports from 3 professional analysts.
|15Mar17 09:58||RNS||Director/PDMR Shareholding|
|09Mar17 11:19||RNS||Director/PDMR Shareholding|
|07Mar17 07:00||RNS||Half Yearly Report|
|02Mar17 10:00||RNS||PureCircle Completes Stevia Plant Expansion|
|31Jan17 07:00||RNS||Total Voting Rights|
|30Jan17 07:00||RNS||Removal of Restriction on Imports into the U.S.|
|26Jan17 16:40||RNS||Second Price Monitoring Extn|
Frequency of research reports
Research reports on
Finding the sweet spot?
13 Mar 17
Despite significant headwinds coming from the US Customs and Border Protection (CBP) blocking its products throughout the half year, PureCircle has weathered the storm well. H117 sales outside the US were up 10%, with total sales down 13.4% despite the company being denied access to a market that previously represented one-third of its revenues, and gross margins holding up remarkably well considering there were adverse mix effects. The innovation pipeline is strong and the scope for stevia use in the food and beverage industry continues to increase.
Consensus eps falling…falling…falling…rising 2.0
29 Apr 16
In January we screened for companies with estimates that had been declining consistently since a year previously, but which had risen in the immediately preceding three months (see our note dated 22 January 2016). We have reviewed the performance of those companies and, given the overall strength of this selection, we have re-run the screen. In the c.3 months since selection, the unweighted average rise was c.34% against a c.11% rise in the main All-Share index. From the same universe as before (some 900 companies) we find 38 companies selected by the screen. We note a number of stocks in the list where we have a supportive stance including: Devro (DVO LN, Buy), James Fisher (FSJ LN, Corporate), Mattioli Woods (MTW LN, Buy) and Spirent Communications (SPT LN, Buy).
New Product Development Enhances the Mix
17 Mar 17
Fever Tree’s (FEVR LN, HOLD, T/P 1250p) announces preliminary 2016 results on Tuesday 21st March. We forecast revenue to increase 72.6% to £102.2m in line with the 24th January trading update, and adjusted diluted EPS to continue its positive momentum to 25.2p (23.7p FY2015). Current consensus appears to be 24.0p (Source: Bloomberg).
21 Mar 17
Fever Tree’s (FEVR LN, HOLD, T/P 1250p) preliminary 2016 results this morning included in line EBITDA and diluted EPS. The company reported £35.8m of EBITDA – marginally ahead of our own £35.6m estimate and in front of £34.9m consensus forecast. Adjusted diluted EPS was 23.7p (+104%), consistent with our estimate (23.7p) but slightly below the 24.0p predicted by consensus (source: Bloomberg). Fever Tree holds an analyst presentation at 9.30am.
Panmure Morning Note 20-03-2017
20 Mar 17
Today’s H1FY17 results are in line with our and consensus expectations, and we are therefore maintaining our FY17 and FY18 PBT estimates. We regard this as a resilient performance given the turbulent backdrop. We leave our BUY rating and 150p TP unchanged to reflect our positive view on FIF’s long-term prospects predicated on; (1) FIF’s broad-based business spread across channel, customer and product providing diversification of opportunity and risk; (2) FIF is wellpositioned in the fast-growing areas (e.g. artisan breads, celebration cakes, “food-to-go”/foodservice) of the UK bakery market; and (3) FIF’s market leading position and size to deliver scale advantage to develop its stated growth opportunities (including targeted accretive acquisitions), further supported by FIF’s sound financial position (H1FY17 net debt/EBITDA of 0.8x).
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
10 for 17
09 Jan 17
As always at the start of a year, there are significant uncertainties about the year ahead but I think in 2017, the level of uncertainly has decisively moved up a gear. In fact, a leading economist at the LSE, Ethan Ilzetzki, was recently quoted as saying “I view the current global economic environment as the most uncertain in modern history”. Wow.
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.